The study ‘One to Three’ will compare the treatment completion of daily dose of Rifapentine and Isoniazid for a month (1HP) to the weekly dose of Rifapentine and Isoniazid for three months (3HP) in persons living with HIV in Pune.
The key aims of the trial are: generate evidence for HIV and TB programmes to integrate alcohol reduction counselling; bring about behavioural changes to ensure lower alcohol intake.